OBJECTIVE: To investigate the pharmacodynamics of Rujikang naoemulsion preparation in the treatment of hyperplasia of mammary glands in mice. METHODS: The ICR mice were randomly divided into normal group

model group and treatment group [bromocriptine group（ coated with bromocriptine）

high-dose group（ coated with high-dose Rujikang naoemulsion preparation） and low-dose group（ coated with low-dose Rujikang naoemulsion preparation） ]. The mouse model of mammary gland hyperplasia was established

after 30-day drug intervention on the treatment group

the changes in body mass

areola and nipple diameters were observed

the serum estradiol（ E

2

） and progesterone（ P） levels were measured

the changes in pathogeny structure of breast tissue were observed by hematoxylin-eosin staining method

the apoptotic cells were observed by TUNEL staining method

the Caspase-3 and Bcl-2 protein expression were detected by Western blot method. RESULTS: Compared with the model group

mice in the treatment group had lower body mass（ P

<

0. 05）

shorter areola and nipple diameter（ P

<

0. 01

P

<

0. 001）

lower E

2

level（ P

<

0. 05）

higher P level（ P

<

0. 05）

fewer in number of apoptotic cells（ P

<

0. 001）

up-regulated Caspase-3 protein expression（ P

<

0. 001）

and down-regulated Bcl-2 protein expression（ P

<

0. 01）

differences were statistically significant. Compared with the model group

structures of mammary tissue and epithelial cell of the treatment group were basically restored to normal. CONCLUSIONS: The Rujikang naoemulsion preparation can significantly inhibit hyperplasia of mammary glands in mice caused by hormonal disorder.